Anti-Human Claudin-18.2 Reference Antibody (Ciletatug, RUO) (HX126246)

Name: Anti-Human Claudin-18.2 Reference Antibody (Ciletatug, RUO)
Brand: abinScience
SKU: HX126246
Price: 176 USD
Availability: InStock

데이터시트 제품 공유 정보 복사

가격(USD):

사양:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

수량:

문의하기

개요
이미지
참고 문헌
데이터시트
SDS

개요

카탈로그 번호	HX126246
설명	ciletatug (HX126246) is a research-grade recombinant antibody targeting CLDN18.2. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research.
종 반응성	Human
응용 분야	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
숙주 종	Human
클론성	Monoclonal
이소타입	IgG1, Kappa
타겟	CLDN18.2, Claudin-18.2
내독소 수준	< 10 EU/mg
순도	>95% as determined by SDS-PAGE.
등록번호	P56856-2
형태	Liquid
저장 완충액	0.01M PBS pH 7.4. 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요.
배송	In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
안정성 및 저장	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
대체 이름	2897622-41-0
배경	Claudin-18 (CLDN18.2) is a ~27 kDa protein. Involved in alveolar fluid homeostasis via regulation of alveolar epithelial tight junction composition and therefore ion transport and solute permeability, potentially via downstream regulation of the actin cytoskeleton organization and beta-2-adrenergic signaling. Required for lung alveolarization and maintenance of the paracellular alveolar epithelial barrier. Acts to maintain epithelial progenitor cell proliferation and organ size, via regulation of YAP1 localization away from the nucleus and thereby restriction of YAP1 target gene transcription. Acts as a negative regulator of RANKL-induced osteoclast differentiation, potentially via relocation of TJP2/ZO-2 away from the nucleus, subsequently involved in bone resorption in response to calcium deficiency. Mediates the osteoprotective effects of estrogen, potentially via acting downstream of estrogen signaling independently of RANKL signaling pathways. CLDN18.2 is the therapeutic target of zolbetuximab (Vyloy).
참고사항	For research use only. Not suitable for clinical or therapeutic use.